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Purpose: To develop a simple, sensitive and rapid reverse phase HPLC method for the simultaneous 
analysis of metoprolol succinate and hydrochlorothiazide in a solid dosage form. 
Methods: The drugs were analysed by a reverse phase C-18 column using 50mM di-sodium hydrogen 
phosphate:methanol:acetonitrile in a ratio of 525:225:250 as mobile phase. The flow rate was 1 ml/min 
and the compounds were detected by a UV-detector at 222 nm at a column temperature of 24 ± 2 ºC. 
The method was statistically validated for linearity and accuracy.  
Results: The retention time and drug content of metoprolol succinate and hydrochlorothiazide were 5.38 
min, 96.05 % and 3.04 min., 97.64 %, respectively. 
Conclusion: The study shows that the developed method is simple and accurate and that it would be 




Keywords: Metoprolol succinate; Hydrochlorothiazide; Simultaneous analysis; High performance liquid 
















*Corresponding author:  E-mail: sghosh38@sancharnet.in, brijesh_csir@yahoo.co.in; Tel: 0373-2370254; Fax:     
0373-2370323 
Brijesh et al  
Trop J Pharm Res, December 2009; 8 (6): 540 
INTRODUCTION 
 
Metoprolol succinate is a beta-blocker and 
while hydrochlorothiazide is a potent thiazide 
diuretic that enhances natriuresis, leading to 
reduction in plasma volume and cardiac 
output. Therefore, it is used widely alone or in 
combination with other antihypertensive 
drugs for the treatment of cardiovascular 
disorders, viz, hypertension, angina, and 
congestive cardiac failure [1-4]. Chemically, 
metoprolol succinate is 2-propanol, 1-[4-(2-
methoxyethyl) phenoxy]-3-[(1-methylethyl) 





Both drugs are official in the British 
Pharmacopoeia and United States 
Pharmacopoeia but their combination is not 
and, to the best of our knowledge, no official 
method has yet been developed for their 
separation and assay [5,6]. A literature 
survey revealed spectrophotometric and 
HPLC methods for the determination of 
metoprolol succinate and hydrochlorothiazide 
individually in pharmaceutical dosage forms 
as well as in biological fluids [7-16]. A new 
drug application (NDA) has been submitted to 
FDA (U.S. Food and Drug Administration) by 
AstraZeneca, a multinational pharmaceutical 
firm, in respect of the above combination [17].  
Thus, application of an HPLC method with 
high sensitivity and selectivity will find use for 
the determination of metoprolol succinate and 
hydrochlorothiazide in pharmaceutical 




All solvents were of HPLC grade and 
reagents were of analytical grade. Acetonitrile 
and methanol were obtained from Merck
®
; 
orthophosphoric acid and di-sodium 
hydrogen phosphate were purchased from 
Rankem (Ranbaxy). Water was purified with 
Milli-Q Millipore system. All the solvents and 
solutions were filtered through a membrane 
filter (Millipore Millex
®
-FH, filter units, 
Durapore-PVDF, Polyethylene, 0.22µm pore 
size) and degassed before use.  
 
The active pharmaceutical ingredients (API), 
metoprolol succinate (assigned purity: 99.1%) 
and hydrochlorothiazide (assigned purity: 
100.0%), were donated by M/s Ajanta 
Pharma Limited, Mumbai and M/s Ipca 
Laboratories, Mumbai, India, respectively, 





Tablets, each containing 95 mg of metoprolol 
succinate and 12.5 mg of hydrochlorothiazide 
together with other tablet excipients (lactose - 
172 mg; starch - 15 and 35 mg for paste and 
powder respectively; magnesium stearate - 2 
mg and talc - 18 mg) were prepared in the 
laboratory as follows. Metoprolol succinate, 
hydrochlorthiazide and lactose were mixed 
well, and the mixture was moistened 
uniformly with 10% starch mucilage. 
Granules were then prepared by passing it 
through a 1.41 mm aperture sieve and dried 
in an oven at 60 
0
C for 45 min. The dried 
granules were passed through 0.84 mm 
aperture sieve, and mixed thoroughly with dry 
starch and talc. Three batches, similar in 
composition and coded MSHT-1, MSHT-2, 
and MSHT-3, respectively, were made. 
Tablets (diameter, 10 mm and thickness, 
5±0.2 mm) were produced from the 
formulations using a hand operated single 




Quantitative analysis was performed on 
isocratic high performance liquid 
chromatography system (HPLC, Waters, 
Milford, USA) with two Waters 515 pumps, a 
fixed wavelength programmable 2487 dual 
wavelength absorbance detector (Waters, 
Milford, USA) fixed at 222 nm. A guard 
column (C-18, Shim-pack, Merck, Germany), 
reverse phase C-18 column (Lichrospher
® 
Merck, 250×4 mm, 5µm particle size) and 
rheodyne injection valve with 20 µl loop were 
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used. The HPLC system was equipped with a 
software, Millenium
®




All analyses were done at a column 
temperature of 24 ± 2 °C under isocratic 
conditions. The mobile phase consisted of a 
volumetric mixture of aqueous 50mM di-
sodium hydrogen phosphate (pH adjusted to 
5.0 with orthophosphoric acid): methanol: 
acetonitrile (in the ratio of 525:225:250). The 
flow rate was 1.0 ml/min and volume of 
injection was 20 µl. UV detection was made 
at 222 nm. 
 
Preparation of standard  
 
A stock solution of the drugs was prepared by 
dissolving accurately weighed 95 mg of 
metoprolol succinate and 12.5 mg of 
hydrochlorothiazide in a 100 ml volumetric 
flask containing 20 ml mobile phase, warmed 
on a water bath for about 15 min and then 
final volume was raised to 100 ml using the 
mobile phase. Daily working standard 
solutions were prepared by suitable dilution 
of stock solution with mobile phase to 10 ml.  
 
Sample preparation   
 
Mean tablet weight was determined by taking 
the mean of the weights of 20 individual y 
tablets. The tablets were then powdered in a 
mortar with a pestle and an accurately 
weighed portion, equivalent to 95 mg of 
metoprolol succinate and 12.5 mg of 
hydrochlorothiazide, was transferred to a 100 
ml volumetric flask containing 20 ml mobile 
phase. This mixture was shaken well with a 
mechanical shaker for 30 min and then 
warmed on a water bath for about 15 min. 
Extraction was carried out three times with 
the mobile phase (20 ml each time) and the 
final volume was raised to 100 ml. Finally, the 
solution was filtered through a Millipore 
assembly using 0.22 µ filter and appropriately 





Five sets of different concentration levels 
(2.0, 4.0, 8.0, 16.0, 32.0 ppm) were prepared 
for each standard solution. Each of these 
drug solutions (20 µl) was injected into the 
chromatographic system (n = 3). The peak 
area and retention time were recorded, and 
the mean values of peak area ratio were 
plotted against concentrations.  
 
Recovery studies were performed by 
standard addition method. A known 
concentration of working standard was added 
to a fixed concentration of the pre-analysed 
test solution. Recovery (%) was calculated by 
comparing the area before and after the 
addition of the working standard. The same 




Typical chromatograms obtained are shown 
in Figure 1. The retention time (RT) of 
hydrochlorothiazide and metoprolol succinate 
were 3.04 and 5.38 min, respectively. The 
calibration curve showed linearity over a 
concentration range of 2 to 32 µg/ml for both 
drugs, with correlation coefficients of 0.9965 
and 0.9878, respectively; regression 
coefficients (r
2
) were 0.9929 and 0.9971, 
respectively; and representative linear 
regression equations were Y = 0.0426x + 
0.0713 and Y = 0.1273x + 0.045 for 













Figure 1: A typical chromatogram of 
hydrochlorothiazide (RT: 3.04 min) and                   
metoprolol succinate (RT: 5.38 min)   
        5.38 
  3.04 
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The assay results are given in Table 1. The 
mean drug content was found to be 
99.49±1.32 % for metoprolol succinate and 
98.27 ± 0.17 % for hydrochlorothiazide.  
 
 
The recovery test, which was performed in 
triplicate, indicate that mean recovery was 
97.6 ± 0.5 and 96.1 ± 0.49 % for 
hydrochlorothiazide and metoprolol 
succinate, respectively (Table 2).    
 
Table 1: Assay data for combined metoprolol succinate and hydrochlorothiazide (MSHT) formulation 
      
Metoprolol succinate Hydrochlorothiazide  
   Tablet                Dose 
(mg)          
Content/
tab (mg)  
% Label 
Dose 




MSHT-1 95.0 95.7 100.7 12.5 12.5 99.6 
MSHT-2 95.0 93.1 97.9 12.5 12.2 97.4 
MSHT-3 95.0 94.8 99.8 12.5 12.2 97.8 
 
 





Amount of drug 
added (µg) to powdered 
tablet formulation 
Amount (µg) found 
(n = 3) 
% Recovery 
(n = 3) 
0.5 0.472 94.40 
1.0 0.969 96.90 
Metoprolol Succinate 
1.5 1.453 96.87 
0.5 0.463 92.60 
1.0 1.03 103.0 
Hydrochlorothiazide 





In order to develop an effective method for 
the analysis of the drugs in pharmaceutical 
formulations, preliminary tests were 
performed in order to select adequate and 
optimum conditions. Parameters such as 
detection of wavelength, ideal mobile phase 
and their proportions, optimum pH and 
concentration of the standard solution were 
studied. Several binary or ternary eluents 
were tested using various proportions of 
solvents including acetonitrile, methanol and 
di-sodium hydrogen phosphate (50 and 60 
mM).  The flow rate of 1.0 ml/min for the 
mobile phase was selected after these 
preliminary tests. 
 
The development of HPLC methods for the 
determination of drugs has received 
considerable attention over the years 
because of their reiability in the quality control 
of drugs and drug products. The goal of this 
study was to develop a rapid HPLC method 
for the analysis of metoprolol succinate and 
hydrochlorothiazide in a finished tablet 
formulation using a commonly employed 
reverse phase C-18 column with UV detector. 
The proposed method is simple, rapid and 
statistically validated for its accuracy. No 
interfering peaks were found in the 
chromatograms indicating that the tablet 
excipients did not interfere in analysis of 
drugs. The calibration curve showed linearity 
over a concentration range of 2 to 32 µg/ml 
for both drugs and was linear with a 
correlation coefficient of 0.9965 and 0.9878 
for hydrochlorothiazide and metoprolol 
succinate respectively, and with regression 
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coefficient (r
2
) of 0.9929 and 0.9971, 
respectively.  
 
Recovery test, which was performed in 
triplicate, averaged 97.6 ± 0.5 and 96.1 ± 
0.49% for hydrochlorothiazide and metoprolol 
succinate, respectively, indicating that the 






The results of this study showed that the 
developed method is simple and accurate. It 
should be useful for the simultaneous 
determination of metoprolol succinate and 
hydrochlorothiazide in pharmaceutical 
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